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The Carcinogenic Potency Database (CPDB) is a systematic and unifying analysis of results of
chronic, long-term cancer tests. This paper presents a supplemental plot of the CPDB, including 513
experiments on 157 test compounds published in the general literature in 1993 and 1994 and in
Technical Reports of the National Toxicology Program in 1995 and 1996. The plot standardizes the
experimental results (whether positive or negative for carcinogenicity), including qualitative data on
strain, sex, route of compound administration, target organ, histopathology, and author's opinion and
reference to the published paper, as well as quantitative data on carcinogenic potency, statistical
significance, tumor incidence, dose-response curve shape, length of experiment, duration of dosing,
and dose rate. A numerical description of carcinogenic potency, the TD50, is estimated for each set of
tumor incidence data reported. When added to the data published earlier, the CPDB now includes
results of 5,620 experiments on 1,372 chemicals that have been reported in 1,250 published papers
and 414 National Cancer Institute/National Toxicology Program Technical Reports. The plot presented
here includes detailed analyses of 25 chemicals tested in monkeys for up to 32 years by the National
Cancer Institute. Half the rodent carcinogens that were tested in monkeys were not carcinogenic,
despite usually strong evidence of carcinogenicity in rodents and/or humans. Our analysis of possible
explanatory factors indicates that this result is due in part to the fact that the monkey studies lacked
power to detect an effect compared to standard rodent bioassays. Factors that contributed to the
lack of power are the small number of animals on test; a stop-exposure protocol for model rodent
carcinogens; in a few cases, toxic doses that resulted in stoppage of dosing or termination of the
experiment; and in a few cases, low doses administered to monkeys or early termination of the
experiment even though the doses were not toxic. Among chemicals carcinogenic in both monkeys
and rodents, there is some support for target site concordance, but it is primarily restricted to liver
tumors. Potency values are highly correlated between rodents and monkeys. The plot in this paper
can be used in conjunction with the earlier results published in the CRC Handbook of Carcinogenic
Potency and Genotoxicity Databases [Gold LS, Zeiger E, eds. Boca Raton FL:CRC Press, 19971 and
with our web site (http.//potency.berkeley.edu), which includes a guide to the plot of the database, a
complete description of the numerical index of carcinogenic potency (TD50), and a discussion of the
sources of data, the rationale for the inclusion of particular experiments and particular target sites,
and the conventions adopted in summarizing the literature. Two summary tables permit easy access
to the literature of animal cancer tests by target organ and by chemical. For readers using the CPDB
extensively, a combined plot on diskette or other format is available from the first author. It includes
all results published earlier and in this paper, ordered alphabetically by chemical. A SAS database is
also available. Key words: animal cancer test, carcinogenic potency, database, human carcinogen,
monkey neoplasm, TD50. - Environ Health Perspect 107(suppl 4):527-600 (1999).
http.//ehpnetl.niehs.nih.gov/docs/1999/suppl4/527-600gold/abstract.html
Background
The Carcinogenic Potency Database (CPDB)
is a systematic and unifying analysis of the
published results of the diverse literature of
chronic, long-term animal cancer tests on
individual chemicals. The CPDB standardizes
the experimental results and creates an acces-
sible resource widely used to address a variety
ofresearch and regulatory issues in carcino-
genesis. All results in the CPDB prior to this
paper are presented in an easily readable plot
format in the 1997 HandbookofCarcinogenic
Potency andGenotoxicity Databases (1), which
includes all experimental results published
in several papers in Environmental Health
Perspectives beginning in 1984 (2-7). This
paper is a supplement to the CPDB, report-
ing bioassay results published in the general
literature in 1993 to 1994 and in Technical
Reports ofthe National Toxicology Program
(NTP) in 1995 to 1996. Our analyses are
presented in the same plot format as the ear-
lier plots in EnvironmentalHealth Perspectives
(2-7) and in the CRC handbook (1). Data
are reported for 513 new experiments on 157
chemicals. When added to the data published
earlier, the CPDB now includes results of
5,620 experiments on 1,372 chemicals that
have been reported in 1,250 published papers
and 414 National Cancer Institute (NCI)/
NTP Technical Reports.
In the CPDB, detailed information and
analyses important in the interpretation of
bioassays are reported on each experiment
(whether positive or negative for carcino-
genicity), including qualitative data on strain,
sex, target organ, histopathology, and author's
opinion, as well as quantitative information
on carcinogenic potency, statistical signifi-
cance, tumor incidence, dose-response curve
shape, length ofexperiment, dose rate, and
duration ofdosing. Each set ofexperimental
results references the original published paper,
and a series ofappendices defines the codes in
the plot. A numerical description ofcarcino-
genic potency, the TD50 (8), is estimated for
each set of tumor incidence data reported in
the CPDB, thus providing a standardized
quantitative measure for comparisons. In a
simplified way, TD50 may be defined as that
dose rate in mg/kg body wt/day which, if
administered chronically for the standard life
span ofthe species, will halve the probability
of remaining tumorless throughout that
period. Stated differently, TD50 is the daily
dose that will induce tumors in halfofthe test
animals that would have remained tumor free
at zero dose. We estimate TD50 using a one-
hit model (8). TD50 is analogous to LD50,
and a low value ofTD50 indicates a potent
carcinogen, whereas a high value indicates a
weak one. TD50 is often within the range of
doses tested and does not indicate anything
about carcinogenic effects at low doses
because bioassays are usually conducted at or
near the maximum tolerated dose (MTD).
The range ofTD50 values is at least 10 mil-
lionfold for carcinogens in each sex ofrat or
mouse (1,9).
The CPDB is exhaustive in that it includes
all published results ofexperiments that meet
a set of inclusion criteria designed to measure
potency; however, because many tests do not
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meet the criteria, not all cancer tests are
included. No attempt has been made to per-
form an evaluation ofwhether a compound
induced tumors in any given experiment;
rather, the opinion ofthe published authors is
presented as well as the statistical significance
oftheTD50 calculated from their results.
In presenting this supplement to the
CPDB, our intention is that the material be
used as follows, in conjunction with the CRC
Handbook of Carcinogenic Potency and
Genotoxicity Databases (10) and/or with our
fully searchable, 100-page web site on the
World Wide Web (http://potency.berkeley.
edu), which has been accessed by individuals
from 111 countries:
* Complete results for each experiment in
the CPDB to date are obtainable by using
the plots in the CRC handbook (1) and
the present paper.
* Detailed descriptions ofthe methods used
to develop the CPDB and a guide on how
to read the plot format are given in the
CRC handbook and on the web site. The
methods page (http://potency.berkeley.eduI
text/methods.html) describes inclusion rules,
sources ofdata, statistical methods on esti-
mate TD50, selection oftissue and tumor
types to indude, estimation ofthe average
daily dose rate, and extrapolation ofTD50
to the standard life span ofeach species.
The guide to the plot (http://potency.
berkeley.edu/text/guide.html) uses a sample
experiment to describe each field ofthe
plot format; special analysis and standardi-
zation methods for the NCI/NTP bioas-
says are also reported.
* A complete list ofreferences that are the
source ofbioassay results in the CPDB is
provided on the web site, including
papers in the plot in this present paper
(http://potency. berkeley. edultexti
CPDBreferences.html).
* Two summary tables on ourweb site have
been updated to include the experimental
results presented in this paper. The
Summary Table by Chemicals in the
CPDB (http://potency.berkeley.edu/chemi-
calsummary.html) is organized alphabeti-
cally by chemical name and summarizes
results for each sex-species group ofrats,
mice, hamsters, dogs, and monkeys on
positivity, target organ, and potency
(TD50). Chemicals with no evidence of
carcinogenicity are included. Information
is reported on each chemical about
mutagenicity in Salmonella, whether
potency values vary greatly within a
species, and whether there is more than
one positive test in each species in the
CPDB. The Summary Table ofTarget
Organs in the CPDB (http://potency.berke-
ley.edulpathology.html) organizes results
from the CPDB by target organ so that
researchers can quickly determine all
chemicals that induce tumors in each
species at a given site, e.g., mammary
gland or liver. This table includes only
positive chemicals; results are organized
by target organ, species, and mutagenicity
in Salmonella. The table indicates whether
each carcinogen has tests in another species
in the CPDB and whether the chemical is
positive in another species. In combination
with the plots of the CPDB, these two
tables provide a comprehensive summary
ofthe field oflong-term chronic bioassays
and give full citations to each publication
on eachchemical andeach target site.
For readers using the CPDB extensively, a
combined plot on diskette or other format
is available from the first author that
includes all results published earlier and in
this paper, ordered alphabetically by chem-
ical. A SAS database is also available (see
http://potency.berkeley.edu/ordeform. html).
CPDB Plot in This Supplement
This plot ofthe CPDB analyzes results of513
long-term, chronic experiments on 1 57
chemicals, including tests in rats, mice, ham-
sters, and monkeys. Many chemical classes
and compounds with a variety of uses are
included: a) drugs, e.g., fluvastatin, codeine,
ritalin, phenolphthalein, tamoxifen, dehydro-
epiandrosterone (DHEA), and potassium
bicarbonate; b) industrial chemicals, e.g., ace-
tonitrile, methyl tert-butyl ether (MTBE),
nickel sulfate hexahydrate, sodium dichro-
mate, and isoprene; c) pesticides and food
additives, e.g., captan, captafol, piperonyl
butoxide, ethyl acrylate, citric acid; and
d) naturally occurring components offood,
e.g., phenethyl isothiocyanate, 2-amino-i-
methyl-6-phenylimidazo[4,5-b]pyridine
(PhIP), catechol, L-ascorbic acid, and ethyl
alcohol. Eighty-three of the 157 chemicals
were already included in the database, and we
have flagged these names in the plot with
triple asterisks (***). The TD50 values for the
compounds in this plot fall within the 10
millionfold range reported earlier. The posi-
tivity rate among chemicals reported here,
based on the original author's evaluation, is
94/157 (60%), which is similar to the rate for
thedatabase as awhole.
The experimental results reported here
reflect recent changes in the field ofanimal
cancer testing. For NTP bioassays, for exam-
ple, the standard bioassay protocol now
includes three dose groups and a control; in
contrast, in NCI/NTP Technical Reports
published before 1994, only 8% ofthe experi-
ments had more than two dose groups. In the
general literature, over time fewer experiments
have only one dose group, and in this plot
42% ofthe experiments have more than two
dose groups and a control. In the 1990s there
has also been an increase in the proportion of
experiments that restrict histopathology to
known target sites, indicating investigation of
cocarcinogenic effects in parallel studies or of
mechanisms ofcarcinogenesis. Of the 139
papers in this plot, 16 include data on cell
division rates (indicated by the notecode "C"
on the plot). We have consulted with nearly
halfthe published authors and have received
clarification ofresults or data in addition to
that which appeared in their published papers;
these citations are marked in the plot with
"pers.comm." to indicate personal communi-
cation. For some literature papers we have
been able to obtain from the authors full
lifetable data and have used those results to
estimateTD50 values, e.g., tamoxifen, MTBE.
AnalysesThat Usethe CPDB
During the past 15 years we have published
many papers based on results in the CPDB,
including investigations of methodologic
issues such as reproducibility of bioassay
results and constraints on potency estimation,
questions about extrapolation ofcarcinogenic-
ity between species, estimation ofregulatory
risk, and providing a broad perspective on
cancer risk estimates by ranking possible haz-
ards at typical and average human exposures
to rodent carcinogens. A variety ofexposures
are ranked, including natural chemicals in the
diet, pharmaceuticals, workplace exposures,
pesticide residues, and synthetic pollutants.
Recently, we presented an overview ofthose
results and included the principal findings in
tabular form (9,11). We have now updated
each of the analyses to include the experi-
mental results presented in this paper. The
findings in all cases are similar to the earlier
published results, and we therefore refer the
reader to the earlier overviews (9,11,12;
http://potency.berkeley.edu), which also provide
citations to the original papers on each topic.
We continue to find that about half of all
chemicals tested are carcinogenic in at least
one experiment; about halfare also positive
for several subsets ofthe data, induding natu-
rally occurring and synthetic chemicals (Table
1). We have discussed in several papers the
Table 1. Proportion of chemicals evaluated as carcino-
genicafor several data sets in the CPDB.
Chemicalstested in both rats and mice
Chemicals in the CPDB 350/590 (59%)
Naturally occurring chemicals 79/139 (57%)
Synthetic chemicals 271/451 (60%)
Chemicals tested in rats and/or mice
Chemicals in the CPDB 702/1348(52%)
Natural pesticides 37/71 (52%)
Mold toxins 14/23(61%)
Chemicals in roasted coffee 21/30 (70%)
CPDB, Carcinogenic Potency Database.
'Achemical is classified as positive if the author of at least one
published experiment evaluated results as evidence that the
compound is carcinogenic.
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plausible explanations for the high positivity
rate, induding various high-dose effects (9,11;
http://potency.berkeley.edu).
Comparison of Carcinogenicity
in Monkeys and Rodents
This plot includes analyses of 25 NCI
carcinogenicity studies in rhesus and
cynomolgus monkeys, which lasted up to 32
years. Some ofthe experimental results were
reported in earlier plots ofthe CPDB (these
are marked on the plot with a "j" notecode);
however, we have performed new lifetable
analyses using the final control data that have
recently become available (13). Results for
eight chemicals tested in monkeys byNCI are
reported for the first time. Some ofthe indu-
sion rules and methods ofthe CPDB have
been relaxed for these monkey tests; they are
described inAppendix 1.
Comparison of Positivity
As assessment ofhuman cancer risk is usually
based on studies in rodents, one ideally wants
to know whether rodent carcinogens are
human carcinogens; however, human data are
rarely available. One major goal ofthis series
ofexperiments in monkeys was to determine
whether rodent carcinogens would also be
carcinogenic in nonhuman primates (as mon-
keys are more closely related to humans than
are rodents) and thus provide evidence in
support ofinterspecies extrapolation in car-
cinogenesis (14). Conversely, ifrodents and
monkeys are different with respect to carcino-
genicity under laboratory conditions, then
this casts doubt on the validity of ex-
trapolations from rodents to humans. The
chemicals selected by NCI for use in monkey
studies primarily have strong evidence ofcar-
cinogenicity in rodents, i.e., many positive
rodent experiments with high tumor inci-
dence rates, carcinogenic effects at doses
below the MTD, or short latency periods for
malignant tumor induction (10,15,16). The
strong evidence in rodents for these chemicals
suggests that when compared to other rodent
carcinogens they would be likely to be car-
cinogenic in monkeys. Only one of these
chemicals, arsenic, is not a rodent carcinogen
in standard bioassays; however, it is a human
carcinogen (17).
Table 2 describes positivity for the 25
chemicals tested in monkeys that are reported
in detail in the plot presented here. Several of
the test agents are model rodent carcinogens,
some are nitrosamines or chemotherapeutic
agents with strong evidence in rodents, and a
few are synthetic food additives or pesticides.
Two sweeteners, saccharin and cyclamate,
have weaker evidence ofcarcinogenicity in
rodents than the other chemicals tested.
Several ofthe test agents have been evaluated
by the International Agency for Research on
Cancer (IARC) as human carcinogens
(aflatoxin, arsenic, azathioprine, cyclophos-
phamide, melphalan) (17); of these, only
aflatoxin and melphalan were evaluated as
carcinogenic in these monkeystudies.
Table 2 indicates thatonly 11 of25 chemi-
cals were evaluated by NCI as monkey car-
cinogens under the conditions ofthese studies;
3 had equivocal results, and 11 were not car-
cinogenic (13,18). The NCI evaluations are
based on malignant tumors only. For monkey
carcinogens the tumor yields were higher (see
plot) and the latency period shorter than for
chemicals that were not carcinogenic. For 8 of
the 11 monkey carcinogens, the first tumor
occurred in animals that died before 5 years on
test and for the other 3 carcinogens by 13
years. Nearly all chemicals tested in monkeys
are mutagens in Salmonella and about halfare
not carcinogenic in monkeys. A few chemicals
were not mutagenic, and none ofthem were
carcinogenic in monkeys, e.g., DDT, sodium
saccharin, sodium cyclamate, sodium arsenate.
Possible explanatory factors for lack of
evidence ofcarcinogenicity in monkeys for
these rodent and human carcinogens include
a) a true species difference including species-
specific mechanism ofaction; b) a small num-
ber ofmonkeys on test, making it difficult to
detect an effect; c) an experiment in only
cynomolgus or rhesus monkeys but not both
(Appendix 1); d) dose levels that may have
been too low; e) dose levels that may have
been too high (thus producing toxic effects
that reduced life span and therefore the power
to detect an effect); J) early termination of
experiment before natural death; and g) other
aspects ofexperimental design such as route
ofadministration orlength ofdosing.
Table 2 indicates that experimental
designs varied widely across this series oftests
in monkeys with respect to whether both
cynomolgus and rhesus were tested, number
ofmonkeys on test, length of dosing and
length ofexperiment, and average daily life-
time dose rate compared to rodent average
daily lifetime dose rate. Detailed results on
each experiment are given in the plot, indud-
ing route ofadministration, dose rate, tumor
types and incidence, TD50 and its confidence
limits, andshape ofthe dose response.
We have investigated factors that might
account for the lack ofcarcinogenic effects in
monkeys, while noting that because ofthe
small number ofchemicals, the small number
ofanimals, and the wide variation in proto-
cols, it is difficult to conclude which factors
may be most important. First, the number of
dosed rhesus or dosed cynomolgus monkeys
was generally fewer than 15 (Table 2). Thus
one cannot rule out the possibility that a pos-
itive result might have been obtained with a
larger number ofanimals. Second, the spon-
taneous tumor rate in the large colonycontrol
at NCI is low (13,19); thus, if a tumor
occurred in even one or two of the small
number ofdosed animals, the results are diffi-
cult to interpret. Compared to rodents, which
have a high spontaneous tumor rate, the life-
time spontaneous tumor rate in the NCI
monkey colony is low: in rhesus controls,
19/120 (16%) had tumors (seven malignant),
and in cynomolgus monkeys, 4/106 (4%)
had tumors (three malignant). No type of
tumor occurred spontaneously in more than
two animals, except uterine leiomyoma,
which occurred in 6 rhesus monkeys and 1
cynomolgus monkey.
For the model rodent carcinogens (14),
the testing protocol used a short dosing
period (5 years, i.e., one-fourth the standard
life span of20 years) (Table 2). Under these
stop-exposure conditions only one chemical
(urethane) was carcinogenic, even though the
studies were continued for 20-32 years. In
contrast, all ofthe model carcinogens induce
tumors in rodent experiments lasting less
than 6 months, i.e., less than one-fourth the
standard life span of2 years (15,16). Under
the conditions of the 5-year dosing protocol,
the following model rodent carcinogens
were not carcinogenic in monkeys: 2-acetyl-
aminofluorene, 2,7-acetylaminofluorene,
N,N-dimethyl-4-aminoazobenzene, 3'-
methyl-4-dimethylaminoazobenzene,
3-methylcholanthrene (18). Urethane had the
weakest evidence ofcarcinogenicity among
the monkey carcinogens: the latency period
was longer than those ofother monkey car-
cinogens, and onlyone tumor ofanytypewas
induced, i.e., no sitewas a target site for more
than one animal in a monkey experiment.
Thus, the stop-exposure design was less sensi-
tive than the chronic dosing protocol (which
also gives a higher total dose and higher aver-
age daily dose rate) that is used in standard
rodent bioassays and in most ofthe monkey
experiments. A true species difference cannot
be ruled out, however, because monkeys were
dosed for 5 years of a 20-year life span, i.e.,
one-fourth and this is the same proportion
that produced carcinogenic effects in rodents
for these chemicals, i.e., 6 months ofa 2-year
life span.
A difference in route ofchemical adminis-
tration between monkey tests and the positive
tests in rodents does not appear to be impor-
tant in explaining why many rodent carcino-
gens are not carcinogenic in monkeys. Routes
of administration were more often different
for the rodent carcinogens that were positive
in monkeys than for the rodent carcinogens
that were not carcinogenic in monkeys.
We examined whether the number of
animals on test or the dose rate (mg/kg/day)
may have been factors affecting positivity in
monkeys. Our analysis first found the median
value for the combination of negative and
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Table 2. Protocol characteristics and carcinogenicity of 25 chemicals tested in monkeys by the National Cancer Institute.
Rhesus monkeys Cynomolgus monkeys
Author's opinion of Starting Exposure Experiment Dose Starting Exposure Experiment Dose
carcinogenicity in monkeys number (years) (years) ratioa number (years) (years) ratioa
NOT CARCINOGENIC
2-Acetylaminofluorene
2,7-Acetylaminofluorene
Arsenate, sodium
Cyclamate, sodium
DDT
N,N-Dimethyl-4-aminoazobenzene
3'-Methyl-4-dimethylaminoazobenzene
3-Methylcholanthrene
N-Nitrosodimethylamine
N-Methyl-N'-nitro-N-nitrosoguanidine
Saccharin, sodium
EQUIVOCAL
Adriamycin
Azathioprine
Cyclophosphamide
CARCINOGENIC
Aflatoxin B1
Cycasin mixture (diet)
(IPJ)
IQ
Melphaland
N-Nitroso-N-methylurea
N-Nitrosodiethylamine (diet)
(IPJ)
N-Nitrosodipropylamine
N-Nitrosopiperidine (diet)
(IPJ)
Procarbazine.HCI
Sterigmatocystin
Urethane
10 5 26 0.5(R)
0.1 (M)
7 5 32 ND
9 24 24 0.3 (M)
11 11 25 0.4(R)
0.3 (M)
6 5 20 0.7 (R)
13 5 24 0.8 (R)
9 5 26 0.9(R)
6 10 10 0.4 (R)
2(M)
18 23 23 0.2 (R)
7 23 23 0.009(R)
6
5
6
18
13
18
10
5
2
5
10
15
11
15
18
8
9
13
16
16
13
15
24
8
ND
ND
ND
1 (M)
2 (R)
0.8 (M)
0.4(R)
NDc
NDc
8 16 19 0.2 (R)
0.3 (M)
19 18 22 25 (R)
0.7 (M)
14 22 22 6 (R)
82 20 20 2 (R)
4 3 3 4 (R)
7 12 12 22 (R)
21 (M)
6 20 20 0.6 (R)
0.5 (M)
22 16 23 0.4 (R)
0.7 (M)
11 5 25 2 (R)
0.2 (M)
7
19
9
13
5
6
5
4
8
9
17
6
36
12
19
16
61
5
17
30
6
5
14
24
11
5
23
5
10
15
11
17
18
9
16
18
16
16
12
16
17
5
29
14
24
25
ND
_b
0.3(M)
0.4(R)
0.3(M)
27 0.7 (R)
23 0.009(R)
15
15
16
13
ND
ND
1 (M)
2 (R)
1 (M)
17 0.5(R)
24 NDC
9 1 (R)
0.4(M)
18 0.2 (R)
0.3(M)
22 20(R)
0.6(M)
16 7 (R)
16 2 (R)
12 32 (R)
29(M)
19 0.4(R)
0.8(M)
17 0.09(R)
0.07 (M)
23 2 (R)
0.2 (M)
Abbreviations: CPDB, Carcinogenic Potency Database; IPJ, intraperitoneal injection; IQ, 2-amino-3-methylimidazo[4,5-flquinoline; M, mice; ND, no rodent tests meet inclusion rules of the CPDB, but posi-
tive in other rodent test; R, rats.
aRatio from CPDB of highest monkey daily lifetime dose rate (mg/kg/day)/highest rodent daily lifetime dose rate (mg/kg/day). bNo positive rodent test. Ratio of the negative monkey dose in CPDB to the
highest negative rodent dose is 0.0009 (rats). CMonkeys received a mixture of cycad flour, cycasin, and methylazoxymethanol acetate. There are no rodent tests of this mixture; cycad flour is carcinogenic
in rats. dMelphalan was not carcinogenic in rhesus monkeys.
positive monkey experiments for the number
of monkeys tested and for the ratio of the
monkey dose rate compared to the positive
rodent dose rate. For the number ofanimals
we took the total number ofmonkeys that
started on test for both monkey species com-
bined, as the NCI evaluation ofcarcinogenic-
ity for a chemical did not distinguish between
the two species (18). The median value ofthe
number ofmonkeys on test for the 24 rodent
carcinogens in Table 2 was 19. We found a
significant difference between the monkey pos-
itives and negatives. All ofthe chemicals in
Table 2 that were NOT CARCINOGENIC
in monkeys were below the median number of
animals on test, except DDT. Only a few of
the CARCINOGENIC chemicals were below
the median. The three EQUIVOCAL chemi-
cals were all above the median, thus suggesting
that the greater power provided by more ani-
mals may be a factor in the evaluation of
equivocal compared to not carcinogenic. All of
the model rodent carcinogens had the stop-
exposure protocol, and also had fewer than
the median number ofmonkeys on test, thus
providing aprotocolwithlittle power.
To assess whether the dose in monkeys
(mg/kg/day) was low compared to the positive
doses in rodents (mg/kg/day), we used the
ratio (Table 2) ofthe average daily dose rate
in monkeys to that in rodents, and again
found the median for all chemicals regardless
of carcinogenicity result in monkeys. For
rodents, the dose was taken from a positive
experiment with the same route ofadminis-
tration as the monkey experiment, wherever
possible. Table 1 reports the ratio ofthe high-
est daily average lifetime dose rate in monkeys
(mg/kg/day) to the highest in rats or in mice
from the CPDB (mg/kg/day). The median
for all chemicals was 0.4, indicating that for
half the chemicals tested, the monkey dose
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was about halfthe highest dose that induced
tumors in rodents. The monkey doses were
generally close to the rodent doses, even when
they were lower. We repeated this analysis
three ways, using the ratio in Table 2, the
ratio using the lowest positive high dose in
each rodent species, and the lowest dose at
which tumors were significantly increased in
each rodent species. These measures give
increasing weight to how low a dose in
rodents was tumorigenic, and therefore the
second and third ones produce higher
monkey-to-rodent ratios than the value of
the first, which is presented in Table 2.
Regardless ofwhich dose ratio was selected,
there was no difference between the chemicals
that were carcinogenic in monkeys and those
that were not carcinogenic. The overall differ-
ence in positivity between monkeys and
rodents does not appear to be due to dose
level, as the monkey doses (mg/kg/day) were
generally not much below the doses that
induced tumors in rodents. For the 5 human
carcinogens the monkey doses were similar to
the human carcinogenic doses even for the 3
chemicals that were not evaluated as carcino-
genic in monkeys (arsenic, azathioprine,
cyclophosphamide) (20-22).
Some aspects of the conduct of these
monkey experiments contributed to a lack of
sensitivity for some chemicals that were not
carcinogenic in monkeys. All but one ofthe
positive chemicals were tested in both rhesus
and cynomolgus monkeys, i.e., there were at
least five cynomolgus and five rhesus on test.
For 6 ofthe chemicals that were not carcino-
genic, however, only one monkey species had
five animals on test. Among the 5 human car-
cinogens, only aflatoxin and melphalan were
evaluated as carcinogenic in monkeys; how-
ever, for the others (azathioprine, cyclophos-
phamide and arsenic) the experiments lacked
power to detect a carcinogenic effect because
they were terminated early (by 16 years) even
though the doses were not toxic.
Because the evaluations ofcarcinogenicity
in monkeys were based on malignant tumors
only, whereas evaluations in rodents usually
consider both malignant and benign tumors,
it is possible that ifbenign tumors had been
considered, more monkey studies might have
been evaluated as positive. This was not the
case, however, as there were few benign
tumors in tests of chemicals that were not
carcinogenic, and nearly all were tumor types
that also occur in control monkeys.
As a second general approach to under-
standing the discordance between rodents
and monkeys, we searched on a case-by-case
basis for idiosyncratic factors that mayexplain
why some rodent carcinogens were not car-
cinogenic in monkeys. In a few cases, dosing
was stopped or animals died because oftoxic-
ity, and this may be the reason for a negative
result. For example, for DDT the dose was
neurotoxic to rhesus monkeys and dosing had
to be stopped at 10 years. In cynomolgus,
however, the dose was not neurotoxic, thus
providing a short exposure that may have
been less effective than the exposures for most
chemicals thatwere carcinogenic in monkeys.
Ofthe 4 nitrosamines that were positive in
monkeys, all were tested at doses more than 3
times the rat carcinogenic dose (Table 2). Both
nitrosamines that did not induce tumors in
monkeys were tested at less than halfthe rat
carcinogenic dose. For N-nitrosodimethy-
lamine, which did not induce tumors, the
administered doses produced toxic hepatitis,
and all animals died by 10 years; thus, the ani-
mals may not have lived long enough to
develop tumors. For N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG) a published study
indicates that it is carcinogenic in cynomolgus
monkeys (23). In that positive cynomolgus
experiment (23), MNNG induced stomach
tumors in just 1 year; MNNG was given by
gavage 3 times per month at a 10-fold higher
administered dose than the negative 23-year
NCI rhesus experiment in which administra-
tion was by diet 5 times per week. Thus, a
higher administered dose given less frequently
by a different route to a different monkey
species, induced tumors. One or a combina-
tion ofthese factors likely contributed to the
difference in result fromthe NCI monkeytest.
For the two sweeteners, sodium saccharin
and sodium cyclamate, doses were selected on
the basis ofhuman consumption (14). The
saccharin dose was equivalent to 5 cans ofdiet
sodadaily, and thecyclamate dose was equiva-
lent to 30 cans daily (18). The average daily
dose rate ofsodium saccharin gave the lowest
dose ratio ofall chemicals (0.009) (Table 2),
and sodium cyclamate was also relatively low
(0.3). Neither chemical was carcinogenic in
monkeys. In rats, induction ofbladder tumors
from sodium saccharin appears to require a
high dose and is related to development ofa
calcium phosphate-containing precipitate in
the urine (24). At the low dose administered
to monkeys, there was no effect on the urine
or urothelium, and no evidence ofincreased
urothelial cell proliferation or offormation of
solid material in the urine (25). Thus, one
would not expect to find a carcinogenic effect
under the conditions of the NCI study in
monkeys. Additionally, however, there maybe
a true species difference, because primate
urine has a low concentration ofprotein and
is less concentrated (lower osmolality) than rat
urine (25). Human urine is similar to monkey
urine in this respect (24).
Six ofthe chemicals tested were antineo-
plastic and immunosuppressive drugs.
Monkeys were administered doses within a
factor of 2 of the human therapeutic doses,
which are also similar to doses that induced
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tumors in rodents (Table 2). Three ofthese
drugs were carcinogenic to monkeys (melpha-
lan, N-methyl-N-nitrosourea, procarbazine),
and three were evaluated as EQUIVOCAL
(adriamycin, azathioprine, cyclophospha-
mide). Experiments with all three of the
EQUIVOCAL drugs were less sensitive than
a standard life span study because they were
terminated by 16 years (adriamycin because
of cardiotoxicity). For azathioprine and
cyclophosphamide the doses were not toxic.
We note that most ofthe chemicals that
are carcinogenic in monkeys are naturally
occurringchemicals (Table 2). Among 12 nat-
ural chemicals tested in monkeys, 8 are posi-
tive (67%), whereas among 13 synthetic
chemicals only 3 are positive (23%). Two
chemicals, both naturally occurring, induced
tumors rapidly in monkeys: N-nitrosodi-
propylamine (in 3 years) and 2-amino-3-
methylimidazo[4,5-f]quinoline (IQ) (in 8
years). These results in monkeys are consistent
with the finding that among the agents that
IARC has evaluated as human carcinogens,
64% (35/55) arenaturallyoccurring (15,17).
Comparison ofTarget Sites
and Potency
Concordance in target sites according to the
published author's opinion is reported in
Table 3 for 11 chemicals that are positive in
monkeys and rodents in the CPDB. This
analysis is complicated by two facts: first, the
evaluation ofcarcinogenicity for the monkey
studies was based on malignant tumors only
(18), whereas in rodents, evaluations ofcar-
cinogenicity often include benign tumors.
We have indicated with an asterisk (*) in
Table 3 those target sites for which the
author's evaluation was based on a tumor
increase that included benign tumors. A sec-
ond complication ofthis analysis is the fact
that there are frequently many positive exper-
iments in rodents for a chemical; repeated
testing provides an increased chance of
finding a target site in common between
monkeys and rodents.
The liver is the most common target site
ofchemically induced cancer in monkeys and
rodents (Table 3), even among the chemicals
that were noncarcinogenic in monkeys.
Unlike rodents, monkeys had no spontaneous
liver tumors in these lifetime studies (13). We
note that among chemicals that are positive in
both monkeys and rodents, there is a target
site in common between monkeys and at least
one rodent species for all chemicals except
melphalan, which was evaluated as carcino-
genic in monkeys on the basis of"all malig-
nant tumors" (13). As expected, the liver is
the most frequent site in common between
monkeys and each rodent species. Only 3 car-
cinogens have a target site other than liver in
common between rodents and monkeys
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Table3. Comparison oftarget sitesaforeleven chemicalsthatarecarcinogenic in monkeys and rodents.
Chemical agent Rhesus monkeys Cynomolgus monkeys Rats Mice
AflatoxinB, Liver, gall bladder/bile Liver, gall bladder/bile Liver, *colon, kidney
duct, vascularc duct, vascularc
Cycasin mixture Liver, kidney Liver Liver, large intestined
IQ Liver Liver, clitoral gland, large and small Liver, *forestomach, *lung
intestine, mammary gland, oral cavity,
*pancreas, *preputial gland, *sebacious
gland, skin, *urinary bladder, *vascular,c
Zymbal's gland
Melphalan - "All malignanttumors" Peritoneum *Lung, lymphosarcoma
NNitrosodiethylamine Liver Liver Liver, esophagus, *kidney, oral cavity,
*stomach, vascularc
N-Nitrosodipropylamine Liver Liver, *esophagus, nasal cavity
NNitroso-Nmethylurea Uppergastrointestinal tract Uppergastrointestinal tract Forestomach, *lung, *nervous system Stomach,vascular
N-Nitrosopiperidinee Liver Liver Liver, esophagus, nasopharynx *Liver, forestomach, *lung
Procarbazine.HCI Leukemia Leukemia Leukemia,dbrain, lymphoma, mammary Leukemia,dbrain, *lung, lymphoma,
gland lymphosarcoma, uterus
Sterigmatocystin Liver Liver, vascularc Vascular
Urethanebe Liver, vascular,cjejunum Lung, vascular,c pancreas 'All malignanttumors" Liver, *lung, vascular,c reticulum
cell sarcoma
IQ,2-amino-3-methylimidazo[4,5-flquinoline.
*When tumors were induced in monkeys and rodents atthe same target site, the site is listed first for each species and is italicized. In monkeys, opinions are based on malignant tumors. In rats and mice,
asterisk(*) indicates thatthe author's opinion fora targetsite included benign tumors. hOnly one monkey in each indicated species had a tumoratthe target site. cVasculartumors in the liver. dForcycasin,
results in rats are from a bioassay of cycad flour 115). For procarbazine.HCI, leukemias were induced in bioassays that did not meet inclusion criteria in the Carcinogenic Potency Database ( 15). N-
Nitrosopiperidine and urethane were alsotested in hamsters. For Nnitrosopiperidine, target sites in hamsters were similar to those in rats and mice(liver, digestive tract, respiratory system); for urethane,
the sites in hamstersweredifferent.
(Table 3): N-nitroso-N-methylurea (gastroin-
testinal), procarbazine.HCI (leukemia), and
urethane (lung and liver hemangiosarcoma).
Thus, while there is some support for target
siteconcordance, it is primarilyin liver.
The predominance ofliver as a target site
in laboratory studies in rodents and monkeys
is noteworthy because in the United States,
human liver cancer is rare. Chronic inflamma-
tion ofthe liver caused by Hepatitis B and C
viruses is a common cause ofliver cancer in
Asia andAfrica (26). The rodent liver may be
a common site in carcinogenesis bioassays
because the administered doses are high, and
the liver is the primary site for detoxification.
High doses can frequently cause increased
liver cell proliferation by inducingcytotoxicity
and regeneration This effect is similar to what
is seen in the chronic hepatitis-induced
inflammation in humans. High doses can also
increase cell proliferation byother means such
as peroxisome proliferation, inhibiting apop-
tosis with an accumulation ofcells (especially
in foci), inducing apoptosis with consequent
regeneration, orbyothermechanisms (27).
Carcinogenic potency values are highly
correlated between monkeys and rodents for
the chemicals that are carcinogenic to both
(r = 0.79 for log TD50). This result is
expected, given the similarity in doses that
were administered to rodents and monkeys
(Table 2: "Dose ratio") and the fact that
potency estimates are constrained to a narrow
range about the high dose tested (28,29).
Given the wide range ofadministered doses
across chemicals, the correlation in potency
follows statistically (28).
Half the 22 rodent carcinogens in the
CPDB that have been tested byNCI in mon-
keys were not carcinogenic in monkeys,
according to the published authors. This
overall result does not provide strong evi-
dence ofthe validity ofextrapolation ofcar-
cinogenicity between species. Our analysis
indicates, however, that this result is due at
least in part to the fact that the monkey
studies lacked power to detect an effect com-
pared to standard rodent bioassays. Factors
that contributed to the lack ofpower are the
small number ofanimals on test, astop-expo-
sure protocol for model rodent carcinogens,
in a few cases toxic doses that resulted in
stoppage ofdosing or termination of the
experiment, and in a few cases low doses
administered to monkeys orearly termination
ofthe experiment even though the doses were
not toxic. Among chemicals carcinogenic in
both monkeys and rodents, there is some sup-
port for target site concordance, but it is pri-
marily restricted to liver tumors. Potency
values are highlycorrelated as expected.
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